



TAJ
TAJ GROUP
PHARMACEUTICAL
BUSINESS

TAJ PHARMACEUTICALS LIMITED

FINANCIAL REPORT 2006

**DISCLAIMER****THIS PRESENTATION IS NOT AN ADVERTISEMENT OF SECURITIES IN ANY JURISDICTION.****NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.**

This document includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the fact that they do not only relate to historical or current events. Forward-looking statements often use words such as "anticipate", "target", "expect", "estimate", "intend", "expected", "plan", "goal" believe", or other words of similar meaning. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances, a number of which are beyond Company's control. As a result, actual future results may differ materially from the plans, goals and expectations set out in these forward-looking statements. Any forward-looking statements made by or on behalf of the Company speak only as at the date of this announcement. Save as required by any applicable laws or regulations, the Company undertakes no obligation publicly to release the results of any revisions to any forward-looking statements in this document that may occur due to any change in its expectations or to reflect events or circumstances after the date of this document. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States. This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments, i.e., investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (c) high net worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as "relevant persons"). The securities are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.





PHARMA BUSINESS



WORLDWID

Taj has been consistently launching new products, which includes not only first time launches but also line extensions of existing brands. more...



Welcome to the Taj Pharmaceuticals Limited India. We would like to give you an overview of Taj Pharmaceuticals Limited in India: our background, organization, products, core belief and prospects.





Environmental Stewardship



A matter of course for Taj Pharmaceuticals

Taj Pharmaceuticals has long been aware that only a financially successful company can be active in environmental and social areas and that financial success only results if it acts in an environmentally and socially responsible manner. In this context, we consider sustainable development to mean a long-term process designed to meet the needs of current and future generations.

Safety and environmental protection are two important invariables amid changing values. Thus, the assurance of safety and environmental protection is not only required by law but constitutes an obligation and at the same time a key success factor in all our business dealings.





Taj Group “TAJ PHARMA GROUP” AND SUBSIDIARIES HOLDINGS

CONSOLIDATED INCOME STATEMENT FOR THE YEAR ENDED MARCH 31, 2006 (in Rupees and in Lacs)

	2006	2005
REVENUE	100 462	79 368
COST OF SALES	<u>(40 384)</u>	<u>(32 410)</u>
GROSS PROFIT	60 078	46 958
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	(34 254)	(25 013)
OTHER EXPENSES	<u>(545)</u>	<u>(1 813)</u>
OPERATING INCOME	25 279	20 132
INTEREST EXPENSE	(2 136)	(1 476)
FOREIGN CURRENCY EXCHANGE LOSS	<u>(215)</u>	<u>(111)</u>
PROFIT BEFORE INCOME TAX EXPENSE	22 928	18 545
INCOME TAX EXPENSE	<u>(4 571)</u>	<u>(2 509)</u>
NET INCOME	<u>18 357</u>	<u>16 036</u>



Taj Pharmaceuticals Limited (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investors Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.

The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, included on this website regarding the Company's strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the Company's financial results and outlook, the continued implementation of the Company's strategic plan, the development of the Company's pipeline, the commencement of Phase 3 clinical trials for Puricase (pegloticase) are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company's business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the delay or failure in developing Puricase (pegloticase) and other product candidates; difficulties of expanding the Company's product portfolio through in-licensing or acquisition; not being able to manufacture commercial quantities of our products; not gaining market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; introduction of generic competition for API; fluctuations in buying patterns of wholesalers; potential future returns of API or other products; the Company continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company's products; risks of maintaining protection for the Company's intellectual property; risks of an adverse determination in any future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries and other factors set forth more fully in certain reports filed with the Securities and Exchange Commission, to which investors are referred for further information. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements.



Taj Group “TAJ PHARMA GROUP” AND SUBSIDIARIES HOLDINGS

CONSOLIDATED BALANCE SHEET AT MARCH 31, 2006 (in Rupees and in Lacs)

	2006	2005
ASSETS		
NON-CURRENT ASSETS:		
Property, plant and equipment, net	27 204	23 651
Intangible assets, net	13 040	11 889
	<u>40 244</u>	<u>35 540</u>
CURRENT ASSETS:		
Inventories, net	17 997	13 644
Trade receivables, net	58 073	34 569
Accounts receivable from related parties	2 773	3 737
Other receivables and prepaid expenses	5 933	6 115
Cash	215	314
	<u>84 991</u>	<u>58 379</u>
TOTAL ASSETS	<u>125 235</u>	<u>93 919</u>
EQUITY AND LIABILITIES		
EQUITY:		
Share capital	381	1
Retained earnings	86 941	62 192
	<u>87 322</u>	<u>62 193</u>
NON-CURRENT LIABILITIES:		
Long-term borrowings	10 585	11 233
Deferred tax liability	3 373	1 797
Finance lease obligations, net of current maturities	143	48
	<u>14 101</u>	<u>13 078</u>
CURRENT LIABILITIES:		
Trade payables	7 502	6 599
Current portion of long term borrowings	8 085	2 756
Other payables and accrued expenses	6 050	6 964
Finance lease obligations, current maturities	255	142
Accounts payable to related parties	1 920	2 187
	<u>23 812</u>	<u>18 648</u>
TOTAL EQUITY AND LIABILITIES	<u>125 235</u>	<u>93 919</u>





Taj Group “TAJ PHARMA GROUP” AND SUBSIDIARIES HOLDINGS

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2006 (in Rupees and in Lacs)

	2006	2005
CASH FLOWS FROM OPERATING ACTIVITIES:		
Profit before income tax	22 928	18 545
Adjustments for		
Depreciation and amortization	3 038	2 054
Loss on disposal of property, plant and equipment	217	206
Change in allowance for trade receivables and advances to suppliers	1 544	(500)
Change in obsolescence allowance	97	226
Foreign currency exchange loss on financing and investing activities	215	111
Impairment of other receivables	202	-
Impairment of third party loan	-	946
Interest expense	2 136	1 476
Gain on disposal of a related party investment	(99)	-
Operating profit before movements in working capital	30 278	23 064
Change in		
Inventories	(3 091)	(3 924)
Trade receivables	(21 437)	(13 684)
Accounts receivable from related parties	1 274	(541)
Other receivables and prepaid expenses	715	(637)
Trade payables	280	1 847
Accounts payable from related parties	(457)	215
Other payables and accruals	(1 892)	2 758
Cash flow from operations	5 670	9 098
Income taxes paid	(3 203)	(1 768)
Interest paid	(1 790)	(4 013)
Net cash generated from operating activities	677	3 317
CASH FLOWS USED IN INVESTING ACTIVITIES:		
Purchase of property, plant, equipment	(4 329)	(1 869)
Proceeds from sale of investments	99	-
Purchase of intangible assets	(481)	(1 088)
Net cash used in investing activities	(4 711)	(2 957)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from the issue of shares	380	-
Proceeds from borrowings	7 613	4 284
Repayment of borrowings	(2 766)	(8 078)
(Repayment of)/proceeds from borrowings (to)/ from related parties	(1 565)	5 043
Net cash generated from financing activities	3 662	1 249
EFFECT OF TRANSLATION TO PRESENTATION CURRENCY	273	(1 336)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(99)	273
CASH AND CASH EQUIVALENTS, beginning of year	314	41
CASH AND CASH EQUIVALENTS, end of year	215	314





Taj Group “TAJ PHARMA GROUP” AND SUBSIDIARIES HOLDINGS

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED MARCH 31, 2006 (in Rupees and in Lacs)

	Note	Share capital	Retained earnings	Foreign currency translation reserve	Total equity
Balance at MARCH 31, 2004		1	45 555	2 559	48 115
Profit for the year		-	16 036	-	16 036
Effect of translation to presentation currency		-	-	(1 958)	(1 958)
Balance at MARCH 31, 2005		1	61 591	601	62 193
Profit for the year		-	18 357	-	18 357
Issue of additional shares of OJSC “Veropharm”	15	380	-	-	380
Effect of translation to presentation currency		-	-	6 392	6 392
Balance at MARCH 31, 2006		381	79 948	6 993	87 322



Taj Pharmaceuticals Limited (the “Company”) believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investors Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user’s own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.

The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, included on this website regarding the Company’s strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “will” and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the Company’s financial results and outlook, the continued implementation of the Company’s strategic plan, the development of the Company’s pipeline, the commencement of Phase 3 clinical trials for Puricase (pegloticase) are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company’s business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the delay or failure in developing Puricase (pegloticase) and other product candidates; difficulties of expanding the Company’s product portfolio through in-licensing or acquisition; not being able to manufacture commercial quantities of our products; not gaining market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; introduction of generic competition for API; fluctuations in buying patterns of wholesalers; potential future returns of API or other products; the Company continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company’s products; risks of maintaining protection for the Company’s intellectual property; risks of an adverse determination in any future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries and other factors set forth more fully in certain reports filed with the Securities and Exchange Commission, to which investors are referred for further information. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company’s forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company’s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements.



About Taj Pharmaceutical Limited

Taj Pharmaceuticals Limited is a pharmaceutical company founded and based in India. The company manufactures pharmaceutical formulations and API for India and other countries of world. The company was established in 1995 as an enterprise and in 2004 became a public limited company. As per Mumbai pharmaxil and Chemixil association the company manufactures and exports to countries like Albania, Argentina, Austria, Chile and Iraq. In 1995 pharmaceuticals wing only has a schedule M certification for pharmaceuticals products manufacturing in India. Taj Pharmaceuticals established its manufacturing unit in Gujarat because of government policies in 1999 with WHO / GMP licence. The company in 2003 revived all the old manufacturing units and approached the FDA Gujarat for 4000 new pharmaceuticals drug permissions for the first time in India.

According to the Indian Trade Mark the company owns about 450 brands and 4600 generic manufacturing permissions in India. According to the export data analysis the company was the largest exporter of generic medicines to the Europe and Middle East countries.

www.tajpharma.com

The company medicines are present in France, Georgia, Egypt and CIF countries.



Taj Pharmaceuticals Limited
Working For Healthier World™ INDIA



Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use.
© Copyright 2011 Taj Pharma Group (India). All rights reserved.



Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use.
© Copyright 2011 Taj Pharma Group (India). All rights reserved.

Taj Pharmaceuticals Limited (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investors Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.

The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, included on this website regarding the Company's strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the Company's financial results and outlook, the continued implementation of the Company's strategic plan, the development of the Company's pipeline, the commencement of Phase 3 clinical trials for Puricase (pegloticase) are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company's business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the delay or failure in developing Puricase (pegloticase) and other product candidates; difficulties of expanding the Company's product portfolio through in-licensing or acquisition; not being able to manufacture commercial quantities of our products; not gaining market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; introduction of generic competition for API; fluctuations in buying patterns of wholesalers; potential future returns of API or other products; the Company continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company's products; risks of maintaining protection for the Company's intellectual property; risks of an adverse determination in any future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries and other factors set forth more fully in certain reports filed with the Securities and Exchange Commission, to which investors are referred for further information. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements.

TAJ
TAJ GROUP
PHARMACEUTICAL
BUSINESS

TAJ PHARMA GROUP

Taj Pharmaceuticals Limited

[TAJ GROUP]

TAJ PHARMACEUTICALS LIMITED

تاج فارما سیونٹ کلس نی

U.S.- F.D.A. Standards cGMP & W.H.O Certified
"Working for healthier India"

Regd. Off.: 434, Laxmi Plaza, Laxmi Ind. Estate, New Link Road, Andheri (W), Mumbai - 400 053.
Tel.: 91-22-2637 4592/93, 30601000 Mob.: 09930407744 Fax : 91-22-26341274

Factory: UNIT-I
Plot No. - 1019, Vill. - Sarigam, G.I.D.C. ,
Road No. 10, Dist. - Valsad, State of Gujarat. Pin Code - 396142

Factory: UNIT-II
Vill. Kalgam, Tal. Umargaon, costal highway road,
State of Gujrat. India

Web.: www.tajpharmaceuticals.com | www.tajfordoctors.co.in | E-mail : tajgroup@tajpharma.com / tajpharma@rediffmail.com

CONTACT US

TAJ
TAJ GROUP

TAJ PHARMACEUTICALS LIMITED

"Working for healthier India"

The contents and design of this website, including Authority logos, are the property of the Taj Pharmaceuticals Limited India, and are protected under copyright law and international treaty.

All rights reserved. Except under the conditions described in the Copyright Act 1968 and subsequent amendments, no part of this website may be reproduced or communicated by any process without prior permission in writing from

TAJ
TAJ GROUP
PHARMACEUTICAL
BUSINESS

Copyright © 2004-2011 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice
The products discussed herein may have different product labeling in different countries. The product information provided in this site is intended only for the residents of India.